trending Market Intelligence /marketintelligence/en/news-insights/trending/pXOtXxbWxwxSwt9WOuezSg2 content esgSubNav
In This List

ADMA Biologics prices $45M underwritten common stock offering

Blog

Insight Weekly: US stock market downturn; Chinese bank earnings; Europe's big tech bills

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022


ADMA Biologics prices $45M underwritten common stock offering

ADMA Biologics Inc. priced an underwritten public offering of its 11,250,000 common shares at $4 apiece, targeting to raise about $45 million.

The Ramsey, N.J.-based company also granted the underwriters a 30-day option to purchase up to 1,687,500 additional common shares at the same price.

ADMA plans to use the net proceeds for Asceniv's planned commercial launch during the second half of 2019 and for Bivigam's commercial relaunch.

Asceniv and Bivigam are used to treat primary humoral immunodeficiency disease, a group of disorders involving a compromised or incomplete immune system.

The funds will also be used to expand capacity at the company's Boca Raton, Fla., facility and grow its plasma collection facility network, to procure raw materials to manufacture Asceniv and Bivigam, and for general corporate purposes and other capital expenditures.

The offering is expected to close on May 21.

Jefferies LLC and Raymond James & Associates Inc. are acting as joint book-running managers, while Oppenheimer & Co. Inc. is acting as lead manager for the offering.